Ondine Biomedical Inc. (AIM:OBI)
London
· Delayed Price · Currency is GBP · Price in GBX 10.50
-0.50 (-4.76%)
Jun 13, 2025, 4:35 PM GMT+1
Ondine Biomedical Cash Flow Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | -19.1 | -14.41 | -19.37 | -50.09 | -16.27 | Upgrade
|
| Depreciation & Amortization | 0.57 | 0.59 | 0.49 | 0.51 | 1.22 | Upgrade
|
| Other Amortization | - | - | 1.33 | - | - | Upgrade
|
| Loss (Gain) From Sale of Assets | - | 0.1 | 0.08 | - | - | Upgrade
|
| Stock-Based Compensation | 1.85 | 0.64 | 1.45 | 4.06 | 8.45 | Upgrade
|
| Other Operating Activities | -0.72 | -0.27 | -0.43 | 32.84 | 0.7 | Upgrade
|
| Change in Accounts Receivable | -0.19 | -0.14 | 0.07 | 0.3 | -0.52 | Upgrade
|
| Change in Inventory | -0.33 | 0.1 | -0.34 | -0.67 | 0.09 | Upgrade
|
| Change in Accounts Payable | 2.53 | -0.42 | 0.25 | 2.15 | 0.26 | Upgrade
|
| Change in Other Net Operating Assets | -0.11 | 0.16 | 0.13 | -1.65 | -0.18 | Upgrade
|
| Operating Cash Flow | -15.49 | -13.65 | -16.35 | -12.54 | -6.26 | Upgrade
|
| Capital Expenditures | -0.01 | -0.18 | -0.31 | -0.08 | -0.1 | Upgrade
|
| Investing Cash Flow | -0.01 | -0.18 | -0.31 | -0.08 | -0.1 | Upgrade
|
| Short-Term Debt Issued | 1.65 | - | - | 2.83 | 2.6 | Upgrade
|
| Long-Term Debt Issued | - | - | - | 4.25 | 1.48 | Upgrade
|
| Total Debt Issued | 1.65 | - | - | 7.08 | 4.09 | Upgrade
|
| Short-Term Debt Repaid | -0.54 | - | - | -0.65 | - | Upgrade
|
| Long-Term Debt Repaid | -0.43 | -0.43 | -0.25 | -0.29 | -0.26 | Upgrade
|
| Total Debt Repaid | -0.96 | -0.43 | -0.25 | -0.94 | -0.26 | Upgrade
|
| Net Debt Issued (Repaid) | 0.69 | -0.43 | -0.25 | 6.14 | 3.83 | Upgrade
|
| Issuance of Common Stock | 22.98 | 4.91 | - | 37.73 | - | Upgrade
|
| Repurchase of Common Stock | - | - | - | -0.8 | - | Upgrade
|
| Other Financing Activities | -1.93 | -0.7 | -0.02 | -1.17 | -0.07 | Upgrade
|
| Financing Cash Flow | 21.74 | 3.79 | -0.28 | 41.9 | 6.75 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.55 | -0.09 | 0.34 | -0.05 | -0.08 | Upgrade
|
| Net Cash Flow | 6.79 | -10.13 | -16.6 | 29.24 | 0.32 | Upgrade
|
| Free Cash Flow | -15.5 | -13.83 | -16.66 | -12.62 | -6.36 | Upgrade
|
| Free Cash Flow Margin | -756.47% | -1149.63% | -2610.66% | -491.13% | -355.00% | Upgrade
|
| Free Cash Flow Per Share | -0.06 | -0.07 | -0.09 | -0.16 | -0.09 | Upgrade
|
| Cash Interest Paid | 0.01 | - | 0.02 | - | 0.07 | Upgrade
|
| Levered Free Cash Flow | -7.75 | -8.44 | -7.88 | -6.11 | - | Upgrade
|
| Unlevered Free Cash Flow | -7.73 | -8.41 | -7.86 | -6.11 | - | Upgrade
|
| Change in Net Working Capital | -2.02 | 0.21 | -0.91 | -0.34 | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.